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Abstract The class III antiarrhythmic drug clofilium is known 
to block diverse delayed rectifer K + channels at micromolar 
concentrations. In the present study we investigated the potency 
of clofilium and its tertiary analog LY97241 to inhibit K + 
channels, encoded by the human Ether-a-go-go related gene 
(HERG). CIofilium blocked HERG channels in a voltage- 
dependent fashion with an ICs0 of 250 nM and 150 nM at 0 and 
+40 mV, respectively. LY97241 was almost 10-fold more potent 
(ICso of 19 nM at +40 mV). Other cloned K + channels which are 
also expressed in cardiac tissue, Kvl.1, Kvl.2, Kvl.4, Kvl.5, 
Kv4.2, Kir2.1, or /Ks, were not affected by 100-fold higher 
concentrations. Block of HERG channels by LY97241 was 
voltage dependent and the rate of HERG inactivation was 
increased by LY97241. A rise of [K+]o decreased both, rate of 
HERG inactivation and LY97241 affinity. The HERG $631A 
and $620T mutant channels which have a strongly reduced 
degree of inactivation were 7-fold and 33-fold less sensitive to 
LY97241 blockade, indicating that LY97241 binding is affected 
by HERG channel inactivation. In summary, the antiarrhythmic 
action of clofilium and its analog LY97241 appears to be caused 
by their potent, but distinct ability for blocking HERG channels. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The quarternary  ammonium derivative clofil ium is well 
known for its ant iarrhythmic  efficacy [1]. However ,  clofi l ium 
does not  appear  to be a blocker o f  specific channels but has 
been demonst ra ted  to block a variety o f  cat ion channels at 
micromolar  concentrat ions.  In guinea pig cardiac myocytes 
clofil ium was demonst ra ted  to block the voltage-act ivated 
K + current which is composed of  the slowly and more  rapidly 
act ivat ing conductances  IK~ and IKr, respectively, at concen-  
trat ions as high as 100 gM [2]. However,  it was not  analyzed 
whether  clofi l ium blocks both components  with a similar po- 
tency. Interestingly, in the same study LY97241, a tert iary 
analog of  clofil ium, was shown to block inward rectifier K + 
currents in contrast  o clofil ium. For  cloned cardiac K + chan-  
nels expressed in Xenopus oocytes such as Kv l .2 ,  Kv l .4 ,  
Kv l .5 ,  and /Ks channels  clofi l ium was shown to have dist inct 
IC~0 values ranging from 1 to 100 gM [3 6]. The aim o f  the 
present study was 1) to test HERG channels  for their sensi- 
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tivity for the ant iarrhythmic  lofi l ium and 2) to compare  its 
effects with its tertiary analog LY97241. 
2. Materials and methods 
Handling and injection of Xenopus oocytes and synthesis of cRNA 
has been described previously in detail [7]. The two-microelectrode 
voltage-clamp configuration was used to record currents from Xeno- 
pus laevis oocytes. In several sets of experiments, oocytes were indi- 
vidually injected with cRNA encoding for the K ~ channels HERG [8], 
HERG $631A [9], human LK [10], rat Kvl.1 [11], rat Kvl.2 [12], rat 
Kvl.4 [13], human Kvl.5 [14], rat Kv4.2 [15] or rat Kir2.1 [16]. The 
mutation $620T was introduced into HERG by PCR mutagenesis. 
The mutagenic oligonucleotide covered the unique BglII restriction 
site; the second oligonucleotide located upstream of a unique BstEll 
site. The PCR product was cleaved with these two enzymes and sub- 
cloned into the HERG wild type plasmid. The sequence of the muta- 
genized fragment was confirmed by DNA sequencing. To increase the 
expression level of rat Kv4.2 we subcloned the gene into the expres- 
sion vector pGEMHE [17]. The 2 kb fragment from BstElI (endfilled) 
to EcoRl was introduced into the vector cleaved with Smal and 
EcoRl. 
Recordings were performed at 22°C using a Geneclamp amplifier 
(Axon Instruments, Foster City, USA) with MacLab D/A converter 
and software for data acquisition and analysis (ADlnstruments, Cas- 
tle Hill, Australia). Outward currents through I-tERG channels were 
in general evoked with 0.5-s depolarizing pulses from a holding po- 
tential of -80  mV to +40 mV at 3-s intervals (low-pass filtered at 0.5 
kHz). Tail currents were analyzed at -85  mV. HERG-mediated cur- 
rents were measured as the peak amplitude of the tail currents. Out- 
ward currents through Kvl.1 and Kvl.4 channels were evoked with 
0.5-s and 0.3-s depolarizing pulses, respectively, to 0 mV every 3 s. K ~ 
outward currents through Kvl.2 and Kvl.5 were evoked every 3 s 
with 0.3-s depolarizing pulses to 0 mV and +40 mV, respectively; tail 
currents were analyzed at -30  or -80  mV. The holding potential for 
all Kv channels was -80  mV and the currents were low-pass filtered 
at 1 kHz. l~:s was evoked with 15-s voltage steps to -10  mV from a 
holding potential of -80  mV (filtered at 10 Hz). Kir2.1 currents were 
evoked with 0.5-s hyperpolarizing pulses to -120 mV from a holding 
potential of -40  mV (filtered at 1 kHz). The amplitudes of the re- 
corded currents were measured at the end of the test voltage steps: 
currents through inactivating Kvl.4 channels were measured at their 
maximum. 
The control solution (ND96) contained (mM): NaCI 96, KC1 2, 
CaC12 1.8, MgCI2 1, HEPES 5 (titrated with NaOH to pH 7.4). In 
some experiments he concentration of K + was 0 mM (0 K) or 10 mM 
(10 K). In the 0 K solution no K 4 was added, but additional 2 mM 
NaC1. Because of possible K ~ leak from the oocytes and an incom- 
plete K + wash-out during the experiments we cannot exclude the local 
K ~ concentration at the K + channel pore to be up to 100 p-M. 10 K 
(ND88) contained 88 mM NaCI, 8 mM KC1 and the solution was 
titrated with KOH to pH 7.4. The microelectrodes were filled with 3 M 
KC1 solution and had resistances between 0.5 to 0.9 Mr2. Clofilium 
and LY97241 were a generous gift from Eli Lilly, Indiana, USA. They 
were dissolved in DMSO as stock solutions and added to the control 
solutions before the experiments (maximal DMSO concentration 
<0.1%). Data are presented as means with standard errors 
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3. Results 
(S.E.M.) where n represents the number of experiments performed. 
Concentration-blockade relationships were calculated with the Hill 
equation: inhibition=100*([inhibitor]n/([inhibitor]+ICs0n)), where n 
is the Hill coefficient. Student's t-test was used to test for statistical 
significance which was obtained for p < 0.05. In one batch of oocytes 
we detected HERG channels which were resistent to LY97241 block. 
These cells (about 20%) are indicative of a cellular regulation which 
was not studied in detail; these weakly responding cells were not 
considered for the statistics. 
(A) 
Expression of HERG channels in Xenopus oocytes induced 
K + channels with characteristic properties, i.e. fast inactiva- 
tion at positive potentials and large, slowly decaying tail cur- 
rents upon repolarization [18]. The class III antiarrhythmic 
clofilium inhibited HERG channels in a concentration-de- 
pendent manner with an ICs0 of 150 +9 nM (n = 5) at +40 
mV (Fig. 1A, C). In addition, HERG channel block by clofi- 
lium was voltage dependent; at 0 mV an IC~0 of 252 + 62 nM 
was extrapolated (n= 5). A similar ICs0 for clofilium has been 
reported for Kvl.5 channels, while other cardiac K + channels 
such as /Ks channels appear to have a more than 100-fold 
lower affinity [5,6,19]. The clofilium block of HERG channels 
was almost irreversible; after a washout period of 2 hours 
approximately 40% of the control current could be recovered. 
This possibly indicates a channel block at an intracellular site. 
LY97241 is an analog of clofilium with two chemical mod- 
ifications, a p-substitution of the Cl-  residue by N~O and the 
removal of the ethyl group at the amine function. Whereas the 
C1- substitution by N20 is not expected to change the behav- 
iour of the molecule, the removal of the ethyl residue is sub- 
stantial, as it changes the quarternary, permanently positively 
charged clofilium into a tertiary amine. This tertiary analog of 
clofilium, LY97241, was 10-fold more potent (Fig. 1B, C) in 
inhibiting HERG channels. After depolarizations to +40 mV 
HERG tail currents were half-maximally blocked at a concen- 
tration of 19.0 + 1.3 nM (n = 5), after depolarizations to 0 mV 
an ICs0 of 39.3 + 1.0 nM (n = 5) was determined. To test for 
the channel specificity of LY97241, Kvl.1, Kvl.2, Kvl.4, 
Kvl.5, Kv4.2, Kir2.1, and/Ks channels, whose characteristics 
have been described elsewhere [15,20], were expressed in Xen- 
opus oocytes. At 3 ~tM (100-fold higher concentrations than 
the ICs0 for HERG channels) LY97241 inhibited all of these 
channels by less than 5% (data not shown). 
We could recently describe a voltage-dependent HERG 
channel blockade by the histamine receptor antagonist aste- 
mizole and terfenadine [21] and the antipsychotic haloperidol 
[20]. Blockade of HERG channels by these compounds af- 
fected the rate of HERG inactivation. Similarly, LY97241 
affected HERG inactivation in the present study (Fig. 2). At 
-15  mV, HERG channel inactivation could be fitted by a 
single exponential function with an inactivation time constant 
(Xin~t) of 14.5+ 1.8 ms (n=5). In the presence of 20 nM 
LY97241 xin~t was decreased to 9.5 + 0.6 ms (n = 5). 
HERG channels have been described to be modulated by 
the extracellular K + concentration ([K+]0) [18]. Here we ana- 
lyzed the effects of K+0 on HERG inactivation and LY97241 
sensitivity. An increase in [K+]0 significantly decreased the 
rate of HERG inactivation (Fig. 3A), With nominally 0 
mM, 2 mM, and 10 mM [K+]0 at --15 mV the inactivation 
time constants were 8.0 + 0.4 ms, 14.4 + 0.7 ms, and 19.5 + 0.8 
ms (n=7), respectively. Steady-state inactivation was de- 
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creased from 90.1+0.3% at 2 mM to 83.1+1.4% (n=7) at 
10 mM [K+]0. As shown in Fig. 3B and C, an increase in 
[K+]0 to 10 mM also decreased the LY97241 sensitivity of 
HERG channels. The ICs0 for LY97241 was more than three- 
fold increased (66.8 +4.3 nM; n= 5) at 10 mM [K+]0. 
The mutation $631A in the HERG channel pore region has 
previously been shown to decrease HERG inactivation [9]. 
This mutant also displays a reduced affinity to the histamine 
receptor antagonists astemizole and terfenadine (unpublished 
data) and the antipsychotic haloperidol [20]. Similarly to these 
drugs, the affinity of LY97241 was reduced 7-fold by the 
mutation $631A (Fig. 4B; IC~0 at 0 mV was 279+9 nM; 
n = 5). The pore mutation $620T which was reported to re- 
move channel inactivation more completely than $631A [22] 
showed an even lower sensitivity to LY97241 (Fig. 4 A and B; 
ICs0 at 0 mV was 1.35+0.30 gM; n=6). 
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Fig. l. Blockade of HERG channels by clofilium (A) and LY97241 
(B). HERG channels were activated with depolarizations to +40 mV 
and the tail currents were recorded at -85 mV. The dashed line in- 
dicates the baseline. (C) Concentration-inhibition relation of HERG 
channel block by clofilium and LY97241 at +40 mV. The data rep- 
resent means + S.E.M. The continuous curves are data fits according 
to a Hill equation (see Section 2). 
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Fig. 2. Effects of LY97241 on HERG inactivation. (A) HERG channels were held at -15 mV where they are partially open but mostly inacti- 
vated. A brief repolarization to -100 mV causes a rapid relief of inactivation without significant deactivation. Subsequent depolarization back 
to -15 mV results in large, rapidly inactivating outward currents. Please note that the steady-state current before and after the repolarization 
is identical. (B) LY97241 (20 nM) significantly reduces the time constant for HERG channel inactivation. The data represent means + S.E.M. 
4.  D iscuss ion  
The present paper describes the inhibitory effects of the 
class III antiarrhythmic lofilium and its analog LY97241 
on HERG channels which underlie the cardiac K + conduct- 
ance IKr [18]. The rather low IC50 of 150 nM for clofilium 
block of HERG channels compared to other cardiac K -  
channels (the IC50 for IKs channels which underlie the cardiac 
conductance IK~ is close to 100 gM [6]) suggests that HERG 
channels are the primary targets for the antiarrhythmic action 
of clofilium. 
Our data show a correlation between the sensitivity of 
HERG channels towards clofilium and LY97241 and the 
rate of channel inactivation, suggesting that changes in chan- 
nel configuration during inactivation favour LY97241 bind- 
ing. The inactivation of HERG channels is voltage depend- 
ent; the rate of inactivation increases about 3-fold between 0 
and +40 mV [9]. We now observed a 2-fold higher sensitivity 
of HERG towards LY97241 at +40 mV compared with 0 inV. 
Consistent with this correlation, an increase of [K+]0 from 2 to 
10 mM decreased both, the rate of channel inactivation (by 
about 40%) and the inhibitory potency of LY97241 (about 3- 
fold). Similarly, HERG $631A mutant channels, which dis- 
play a strongly reduced inactivation, are also less sensitive to 
LY97241. In addition, LY97241 increases the rate of HERG 
channel inactivation, similarly as previously reported for the 
antipsychotic drug haloperidol [20]. Consequently, manipula- 
tions affecting HERG channel inactivation also affected their 
inhibition by LY97241. Although we cannot exclude an open- 
channel block as an additional component of HERG channel 
blockade, the present data suggest that conformational 
changes in the HERG channel protein leading to inactivation 
support binding of clofilium and LY97241. 
A similar dependence of drug binding on the inactivated 
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Fig. 3. Effects of [K+]0 on HERG channel inactivation and LY97241 block. (A) The same protocol as in Fig. 2 (A) was used at nominally 0, 
2, and 10 mM [K+]0 as indicated. The currents flowing at --100 mV reflect the relief of HERG channel inactivation which is approximately 
complete at the end of the hyperpolarization. At 2 mM [K+]0 the reversal potential is close to -100 mV. (B) Concentration-dependence of 
HERG channel blockade in 10 mM [K+]0 (ND88). HERG channels were activated with depolarizing steps to +40 mV and inward tail currents 
were measured at -85 mV. The concentration of LY97241 is indicated in nM. As a control, a data trace recording in 2 mM [K+]0 (ND96) is 
included. (C) Dose-dependence of relative inhibition of HERG channels by LY97241. The data represent means_+ S.E.M. The continuous curve 
represents a data fit according to a Hill equation (see Section 2). The dashed curve reflects the data in ND96 (2 mM [K ~]0) as shown in 
Fig. 1C. 
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Fig. 4. Concentration-dependence of LY97241 block of HERG $631A and HERG $620T mutant channels. (A) HERG $620T channels were 
activated with depolarizing steps to 0 mV in ND96 solution. (B) Dose-dependence of relative inhibition of HERG $631A and HERG $620T 
mutant channels by LY97241 with a data fit according to the Hill equation. The data represent means + S.E.M. For comparison, the corre- 
sponding result obtained from HERG wild-type channels (dashed curve) is indicated. 
state of HERG channels has recently been described for the 
antiarrhythmic drug dofetilide [22]. In addition to the muta- 
tion $631A in the external mouth of the channel pore, these 
authors also analyzed a mutation at the inner vestibule of the 
pore ($620T) which had even stronger effects on drug sensi- 
tivity and channel inactivation [22]. It is shown here that this 
mutation is much less sensitive to LY97241 than the wild type 
and the mutant $631A. Thus, it is feasible that intracellular 
residues are important in forming a binding site for both, 
dofetilide and clofilium. In fact, clofilium has been shown to 
block Kvl.5 channels with a much higher potency in inside- 
out versus outside-out patches, suggesting a binding from the 
intracellular side [19]. The extremely slow reversal of HERG 
block by clofilium and LY97241 suggests a similar mechanism 
for these compounds. As the tertiary amine LY97241 is likely 
to penetrate the phospholipid membrane more easily than 
quaternary clofilium, it is conceivable that it has a better 
access to its binding site at the channel protein. 
In summary, the relative specificity and potency of clofilium 
and LY97241 for blocking HERG channels versus other K + 
channels uggests that this block is the primary mechanism for 
their antiarrhythmic a tion. Furthermore, LY97241 is another 
valuable pharmacological tool for the characterization of 
HERG channels. 
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